SynthesisScientific reports2020
Locoregional therapy of the primary tumour in de novo stage IV breast cancer in 216 066 patients: A meta-analysis.
Synthesis in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 2 syntheses or guidelines pooled it, 74 citations in OpenAlex.
- Effect of locoregional surgery in primary tumors on overall survival in patients withFrontiers in oncology · 2025Pooled it
- Locoregional therapy in de novo metastatic breast cancer: Systemic review and meta-analysis.Breast (Edinburgh, Scotland) · 2021Pooled it
- The Role of Locoregional Treatment in Non-Progressive De Novo Metastatic Breast Cancer under Systemic Treatment: A Randomized Controlled Trial (LTMBC).Annals of surgical oncology · 2026Trial
- Aggressive local therapy forOncology reports · 2023Trial
- Variation in Surgical Management of Stage IV Breast Cancer: Local/Institutional and Regional Geographic Considerations.Annals of surgical oncology · 2026Article
- Association Between Axillary Surgical Management and Survival for Patients With De Novo Metastatic Breast Cancer.Annals of surgical oncology · 2026Article
- Effect of Primary Breast Surgery on Prognosis in Breast Cancer Patients Presenting with Isolated Bone Metastases.Cancers · 2026Article
- Prognostic model for pulmonary metastasis in patients with HER2-positive breast cancer: a population-based study.Breast cancer (Tokyo, Japan) · 2026Article
- Analysis of the Current Status of De Novo Metastatic Breast Cancer Surgery in China and the USA: A Multicenter Real-World Study.Annals of surgical oncology · 2026Article
- Locoregional Treatment in De Novo Bone-Only Metastatic Breast Cancer: Prospective, Multi-Institutional Real-World Data, BOMETIN, Protocol MF14-1a.Current oncology (Toronto, Ont.) · 2025Article
- Options for postoperative radiation therapy in patients with de novo metastatic breast cancer.Breast (Edinburgh, Scotland) · 2025Article
- Refining the role of surgery in de novo stage IV breast cancer: the need for biomarkers and mechanistic insights.Breast cancer (Tokyo, Japan) · 2025Article
- The impact of breast surgery and systemic therapy on the survival of patients with de novo stage IV breast cancer.Breast cancer (Tokyo, Japan) · 2025Article
- Review
- Locoregional Radiotherapy in Patients with Advanced Breast Cancer Treated with Cyclin-Dependent Kinase 4/6 Inhibitors Based on Real-World Data.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Time trends in real-world treatment patterns and survival in patients diagnosed with de novo HER2+ metastatic breast cancer: an analysis of the SONABRE registry.Breast cancer research and treatment · 2024Article
- Review
- Novel MRI-guided focussed ultrasound stimulated microbubble radiation enhancement treatment for breast cancer.Scientific reports · 2023Article
- Unravelling oligometastatic disease from the perspective of radiation and medical oncology. Part I: non-small cell lung cancer and breast cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2023Article
- The Role of Primary Surgery inEuropean journal of breast health · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients presenting with de novo stage IV metastatic breast cancer have a complex disease which is normally treated with palliative intent and systemic therapy. However, there is mounting evidence that resection of the primary tumour and/or localised radiotherapy (locoregional therapy; LRT) could be associated with overall survival improvements. We aimed to conduct a meta-analysis to inform decision making. Using the PubMed, Cochrane and Ovid SP databases, a literature review and meta-analysis were conducted to assess the effect of LRT on overall survival. Studies were analysed for the impact of LRT on survival. All forms of LRT resulted in a significant 31.8% reduction in mortality (N = 42; HR = 0.6823 (95% CI 0.6365; 0.7314)). Surgical resection resulted in a significant 36.2% reduction in mortality (N = 37; HR = 0.6379 (95% CI 0.5974; 0.6811)). The prospective trials reported a 19.23% reduction in mortality which was not statistically significant (N = 3, HR = 0.8077 (95% CI 0.5704; 1.1438). 216 066 patients were included. This is the largest meta-analysis regarding this question to date. Our meta-analysis shows that LRT of the primary tumour seems to improve overall survival in de novo stage IV disease. Therefore, this therapeutic option should be considered in selected patients after a careful multidisciplinary discussion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.